Floatz logo

Trastuzumab Emtansine

Epithelial Tumor

University Health Network, Torontoantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Epithelial Tumor cohort.

Asset / SponsorPhaseRating
Enadenotucirev
Akamis Bio
Phase 1/2B
Cobimetinib
University Health Network, Toronto
Phase 2CCC
Capecitabine
University Health Network, Toronto
Phase 2CCC
Brigatinib
University Health Network, Toronto
Phase 2CCC
Ceritinib
University Health Network, Toronto
Phase 2CCC

View all 16 →

Same molecule, other indications

Trastuzumab Emtansine is also rated in:

Breast Inflammatory CarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
breast cancerDormant
BB
Indicative ·
66 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →